Trastuzumab deruxtecan targets HER2 on tumor cells for uptake; once internalized it releases deruxtecan, which inhibits topoisomerase I to cause DNA damage and apoptosis. Topoisomerase I expression alone does not cause cells to be targeted or directly killed.